1
|
Ning Y, Manegold PC, Hong YK, Zhang W,
Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, et al:
Interleukin-8 is associated with proliferation, migration,
angiogenesis and chemosensitivity in vitro and in vivo in colon
cancer cell line models. Int J Cancer. 128:2038–2049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Varney ML, Singh S, Li A, Mayer-Ezell R,
Bond R and Singh RK: Small molecule antagonists for CXCR2 and CXCR1
inhibit human colon cancer liver metastases. Cancer Lett.
300:180–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Oladipo O, Conlon S, O'Grady A, Purcell C,
Wilson C, Maxwell PJ, Johnston PG, Stevenson M, Kay EW, Wilson RH,
et al: The expression and prognostic impact of CXC-chemokines in
stage II and III colorectal cancer epithelial and stromal tissue.
Br J Cancer. 104:480–487. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen
P and Zhu MH: Interleukin-8, a promising predictor for prognosis of
pancreatic cancer. World J Gastroenterol. 18:1123–1129. 2012.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Dimberg J, Ström K, Löfgren S, Zar N,
Lindh M and Matussek A: DNA promoter methylation status and protein
expression of interleukin-8 in human colorectal adenocarcinomas.
Int J Colorectal Dis. 27:709–714. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Chen A, Mumick S, Zhang C, Lamb J, Dai H,
Weingarth D, Mudgett J, Chen H, MacNeil DJ, Reitman ML, et al: Diet
induction of monocyte chemoattractant protein-1 and its impact on
obesity. Obes Res. 13:1311–1320. 2005. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sartipy P and Loskutoff DJ: Monocyte
chemoattractant protein 1 in obesity and insulin resistance. Proc
Natl Acad Sci USA. 100:7265–7270. 2003. View Article : Google Scholar : PubMed/NCBI
|
8
|
Maker AV, Katabi N, Qin LX, Klimstra DS,
Schattner M, Brennan MF, Jarnagin WR and Allen PJ: Cyst fluid
interleukin-1beta (IL1beta) levels predict the risk of carcinoma in
intraductal papillary mucinous neoplasms of the pancreas. Clin
Cancer Res. 17:1502–1508. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Bhat IA, Naykoo NA, Qasim I, Ganie FA,
Yousuf Q, Bhat BA, Rasool R, Aziz SA and Shah ZA: Association of
interleukin 1 beta (IL-1β) polymorphism with mRNA expression and
risk of non small cell lung cancer. Meta Gene. 2:123–133. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Abrahamsson A, Morad V, Saarinen NM and
Dabrosin C: Estradiol, tamoxifen, and flaxseed alter IL-1β and
IL-1Ra levels in normal human breast tissue in vivo. J Clin
Endocrinol Metab. 97:E2044–E2054. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Gorczynski R, Boudakov I and Khatri I:
Peptides of CD200 modulate LPS-induced TNF-α induction and
mortality in vivo. J Surg Res. 145:87–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Coles SJ, Wang EC, Man S, Hills RK,
Burnett AK, Tonks A and Darley RL: CD200 expression suppresses
natural killer cell function and directly inhibits patient
anti-tumor response in acute myeloid leukemia. Leukemia.
25:792–799. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Celik B, Didem Yalcin A, Esra Genc G and
Gumuslu S: Proteomics pattern of peritoneal sApo-2L but not CD200
(OX-2) as a possible screening biomarker for metastatic ovarian,
endometrial and breast carcinoma. J BUON. 20:280–286.
2015.PubMed/NCBI
|
14
|
Gorczynski RM, Clark DA, Erin N and Khatri
I: Role of CD200 expression in regulation of metastasis of EMT6
tumor cells in mice. Breast Cancer Res Treat. 130:49–60. 2011.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Talebian F, Liu JQ, Liu Z, Khattabi M, He
Y, Ganju R and Bai XF: Melanoma cell expression of CD200 inhibits
tumor formation and lung metastasis via inhibition of myeloid cell
functions. PLoS One. 7:e314422012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Erin N, Podnos A, Tanriover G, Duymuş Ö,
Cote E, Khatri I and Gorczynski RM: Bidirectional effect of CD200
on breast cancer development and metastasis, with ultimate outcome
determined by tumor aggressiveness and a cancer-induced
inflammatory response. Oncogene. 34:3860–3870. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
18
|
García-Rodríguez LA and Huerta-Alvarez C:
Reduced risk of colorectal cancer among long-term users of aspirin
and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology.
12:88–93. 2001. View Article : Google Scholar : PubMed/NCBI
|
19
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wang J, He Q, Shao YG and Ji M: Chemokines
fluctuate in the progression of primary breast cancer. Eur Rev Med
Pharmacol Sci. 17:596–608. 2013.PubMed/NCBI
|
22
|
Doll D, Keller L, Maak M, Boulesteix AL,
Siewert JR, Holzmann B and Janssen KP: Differential expression of
the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and
their impact on metastatic disease and survival. Int J Colorectal
Dis. 25:573–581. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Celik B, Yalcin AD, Bisgin A,
Dimitrakopoulou-Strauss A, Kargi A and Strauss LG: Level of
TNF-related apoptosis-inducing-ligand and CXCL8 correlated with
2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon
cancers. Med Sci Monit. 19:875–882. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Narita D, Seclaman E, Anghel A, Ilina R,
Cireap N, Negru S, Sirbu IO, Ursoniu S and Marian C: Altered levels
of plasma chemokines in breast cancer and their association with
clinical and pathological characteristics. Neoplasma. 63:141–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Shirakawa F, Saito K, Bonagura CA, Galson
DL, Fenton MJ, Webb AC and Auron PE: The human prointerleukin 1 β
gene requires DNA sequences both proximal and distal to the
transcription start site for tissue-specific induction. Mol Cell
Biol. 13:1332–1344. 1993. View Article : Google Scholar : PubMed/NCBI
|
26
|
Apte RN, Krelin Y, Song X, Dotan S, Recih
E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, et al:
Effects of micro-environment- and malignant cell-derived
interleukin-1 in carcinogenesis, tumour invasiveness and
tumour-host interactions. Eur J Cancer. 42:751–759. 2006.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A,
Schwall R, Schnitt SJ, Guida A, Hastings HM, Andres J, et al:
Expression of interleukin-1β in human breast carcinoma. Cancer.
80:421–434. 1997. View Article : Google Scholar : PubMed/NCBI
|
28
|
Miller LJ, Kurtzman SH, Anderson K, Wang
Y, Stankus M, Renna M, Lindquist R, Barrows G and Kreutzer DL:
Interleukin-1 family expression in human breast cancer:
Interleukin-1 receptor antagonist. Cancer Invest. 18:293–302. 2000.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Guo L, Liu S, Zhang S, Chen Q, Zhang M,
Quan P, Lu J and Sun X: C-reactive protein and risk of breast
cancer: A systematic review and meta-analysis. Sci Rep.
5:105082015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Han Y, Mao F, Wu Y, Fu X, Zhu X, Zhou S,
Zhang W, Sun Q and Zhao Y: Prognostic role of C-reactive protein in
breast cancer: A systematic review and meta-analysis. Int J Biol
Markers. 26:209–215. 2011.PubMed/NCBI
|
31
|
Ramos-Nino ME: The role of chronic
inflammation in obesity-associated cancers. ISRN Oncol.
2013:6975212013.PubMed/NCBI
|
32
|
Scotece M, Conde J, Gómez R, López V, Lago
F, Gómez-Reino JJ and Gualillo O: Beyond fat mass: Exploring the
role of adipokines in rheumatic diseases. ScientificWorldJournal.
11:1932–1947. 2011. View Article : Google Scholar : PubMed/NCBI
|
33
|
Fietta P and Delsante G: Focus on
adipokines. Theor Biol Forum. 106:103–129. 2013.PubMed/NCBI
|
34
|
Alfadda AA: Circulating adipokines in
healthy versus unhealthy overweight and obese subjects. Int J
Endocrinol. 2014:1704342014. View Article : Google Scholar : PubMed/NCBI
|
35
|
Dossus L, Jimenez-Corona A, Romieu I,
Boutron-Ruault MC, Boutten A, Dupré T, Fagherazzi G,
Clavel-Chapelon F and Mesrine S: C-reactive protein and
postmenopausal breast cancer risk: Results from the E3N cohort
study. Cancer Causes Control. 25:533–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
36
|
Nehete P, Magden ER, Nehete B, Hanley PW
and Abee CR: Obesity related alterations in plasma cytokines and
metabolic hormones in chimpanzees. Int J Inflam. 2014:8567492014.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Gorczynski RM: CD200:CD200R-mediated
regulation of immunity. ISRN Immunology. 2012:6821682012.
View Article : Google Scholar
|
38
|
Rijkers ES, de Ruiter T, Baridi A, Veninga
H, Hoek RM and Meyaard L: The inhibitory CD200R is differentially
expressed on human and mouse T and B lymphocytes. Mol Immunol.
45:1126–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
39
|
Holmannová D, Kolácková M, Kondélková K,
Kunes P, Krejsek J and Andrýs C: CD200/CD200R paired potent
inhibitory molecules regulating immune and inflammatory responses;
Part I: CD200/CD200R structure, activation, and function. Acta Med
(Hradec Kralove). 55:12–17. 2012. View Article : Google Scholar
|
40
|
Fallarino F, Asselin-Paturel C, Vacca C,
Bianchi R, Gizzi S, Fioretti MC, Trinchieri G, Grohmann U and
Puccetti P: Murine plasmacytoid dendritic cells initiate the
immunosuppressive pathway of tryptophan catabolism in response to
CD200 receptor engagement. J Immunol. 173:3748–3754. 2004.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Jenmalm MC, Cherwinski H, Bowman EP,
Phillips JH and Sedgwick JD: Regulation of myeloid cell function
through the CD200 receptor. J Immunol. 176:191–199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
42
|
Yalcin AD, Cilli A, Bisgin A, Strauss LG
and Herth F: Omalizumab is effective in treating severe asthma in
patients with severe cardiovascular complications and its effects
on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.
Expert Opin Biol Ther. 13:1335–1341. 2013. View Article : Google Scholar : PubMed/NCBI
|
43
|
Tural Onur S, Yalcin AD, Celik B and
Gumuslu S: Evaluation of d-dimer, CXCL8, homocysteine, eosinophil
cationic peptide, 25(OH)-vitamin D and immunomodulatory OX-2 levels
in allergic patients. J Asthma. 52:123–127. 2015. View Article : Google Scholar : PubMed/NCBI
|
44
|
Wright GJ, Cherwinski H, Foster-Cuevas M,
Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D,
McClanahan T, et al: Characterization of the CD200 receptor family
in mice and humans and their interactions with CD200. J Immunol.
171:3034–3046. 2003. View Article : Google Scholar : PubMed/NCBI
|
45
|
Nicolini A, Rossi G, Ferrari P and Carpi
A: Clinical and laboratory patterns during immune stimulation in
hormone responsive metastatic breast cancer. Biomed Pharmacother.
68:171–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
46
|
Mikirova N, Casciari J, Rogers A and
Taylor P: Effect of high-dose intravenous vitamin C on inflammation
in cancer patients. J Transl Med. 10:1892012. View Article : Google Scholar : PubMed/NCBI
|